Loading...
The job search that fits your personality
Personalized matches for clinicians, for the coolest jobs in the clinic or beyond
Loading...
The job search that fits your personality
Personalized matches for clinicians, for the coolest jobs in the clinic or beyond
BillionToOne is a next-generation molecular diagnostics company dedicated to developing powerful and accurate diagnostic tests that are accessible to all. Our innovative QCT molecular counting technology significantly enhances the resolution of disease detection using cell-free DNA by over a thousandfold. This groundbreaking technology is integral to our product offerings, including one of our flagship products, Unity Complete™, the only non-invasive prenatal screen capable of assessing fetal risk for both common recessive conditions and aneuploidies from a single maternal blood sample. Leveraging the same molecular counting technology, we've expanded our impact into oncology in 2023 with a pioneering liquid biopsy test, Northstar, that combines treatment selection with monitoring. To date, over 500,000 patients have benefited from our innovative and precise diagnostic tests, and our Annual Recurring Revenue (ARR) has grown from $0 to $125 million in the last ~4 years.
BillionToOne has successfully raised close to $400 million in funding, with a notable $130 million Series D round completed in June 2024, ...
The Real Dill ☘️
DNA sequencing and genetic testing is nothing new, but BillionToOne is taking it one step further performing molecular diagnostics at an incredibly specific level. One of their products, UNITY Fetal Risk Screen, accurately assesses fetal risk for common autosomal recessive conditions without requiring a blood sample from the male partner...that was 96% sensitive for identifying a fetus as high risk across a sample size of over 40,000 patients. Early identification is key for disease management, and by being able to provide direct fetal insights into prevalent autosomal recessive conditions such as Cystic Fibrosis, Spinal Muscular Atrophy, and Alpha and Beta Hemoglobinopathies (including Sickle Cell Disease), more time for better clinical decisioning can occur. Science is amazing. (November 2023)
Jon Lee, PT, DPT, OCS, FAAOMPT, MBA
Pickle co-founder
Precision diagnostic that accurately counts DNA molecules at a single count level to diagnose disease
MissionTo remove the fear of the unknown by providing molecular diagnostics that are accurate, fast, and accessible.
Wow FactorDeveloped a non-invasive prenatal test (NIPT) that assesses fetal risk for recessive conditions and red blood cell antigen incompatibility
Pickle is not affiliated with listed companies unless otherwise noted.